Type 2 Diabetes Mellitus Clinical Trial
— EPIRDEMOfficial title:
Effect of Pistachio Intake on Insulin Resistance and Type 2 Diabetes Mellitus
| NCT number | NCT01441921 |
| Other study ID # | PV11059S |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | September 2011 |
| Est. completion date | September 2017 |
| Verified date | February 2019 |
| Source | Institut Investigacio Sanitaria Pere Virgili |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Hypothesis: Chronic intake of pistachios improves glucose metabolism and insulin resistance status thus contributing to decrease the risk of type 2 diabetes mellitus and its associated abnormalities.
| Status | Completed |
| Enrollment | 50 |
| Est. completion date | September 2017 |
| Est. primary completion date | September 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 25 Years to 65 Years |
| Eligibility |
Inclusion Criteria: - BMI less than 35 kg/m2. - Fasting plasma glucose levels between 100 and 125 mg/dl or - Oral glucose tolerance test of 140 to 199 mg/dl. Exclusion Criteria: - Diabetes mellitus. - Alcohol, tobacco, or drug abuse. - Significant liver, kidney, thyroid, or other endocrine diseases. - Frequent consumption of nuts or known history of allergy to them. - Use of plant sterol, oral antidiabetic drugs, supplemental use of phyllium, fish oil supplements and multivitamins, vitamin E or other antioxidant supplements. - Bad dentures, implying difficulty to chew pistachios. - Being pregnant or wishing to become a pregnant 6 months before or during the study, lactating 6wk before or during the study. - Following vegetarian or weight loss diets. - Other medical or social conditions that difficult the compliance to the intervention. |
| Country | Name | City | State |
|---|---|---|---|
| Spain | Human Nutrition Unit, Faculty of Medicine, Rovira i Virgili University | Reus | Tarragona |
| Lead Sponsor | Collaborator |
|---|---|
| Institut Investigacio Sanitaria Pere Virgili | Western Pistachio Association |
Spain,
Hernández-Alonso P, Cañueto D, Giardina S, Salas-Salvadó J, Cañellas N, Correig X, Bulló M. Effect of pistachio consumption on the modulation of urinary gut microbiota-related metabolites in prediabetic subjects. J Nutr Biochem. 2017 Jul;45:48-53. doi: 10 — View Citation
Hernández-Alonso P, Giardina S, Salas-Salvadó J, Arcelin P, Bulló M. Chronic pistachio intake modulates circulating microRNAs related to glucose metabolism and insulin resistance in prediabetic subjects. Eur J Nutr. 2017 Sep;56(6):2181-2191. doi: 10.1007/ — View Citation
Hernández-Alonso P, Salas-Salvadó J, Baldrich-Mora M, Juanola-Falgarona M, Bulló M. Beneficial effect of pistachio consumption on glucose metabolism, insulin resistance, inflammation, and related metabolic risk markers: a randomized clinical trial. Diabet — View Citation
Hernández-Alonso P, Salas-Salvadó J, Baldrich-Mora M, Mallol R, Correig X, Bulló M. Effect of pistachio consumption on plasma lipoprotein subclasses in pre-diabetic subjects. Nutr Metab Cardiovasc Dis. 2015 Apr;25(4):396-402. doi: 10.1016/j.numecd.2015.01.013. Epub 2015 Feb 7. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Changes from baseline in circulating levels of glucose and insulin according to the intervention arm | Measurement of circulating glucose and insulin levels and cellular glucose uptake | Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm | |
| Secondary | Changes from baseline in inflammatory, oxidative and metabolic risk markers related to glucose/insulin metabolism according to the intervention arm | Cpeptide, resistin, IL-6, IL-18, Ghrelin, leptin, adiponectin, GLP-1 and oxidized LDL will be measured. | Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm | |
| Secondary | Changes from baseline in haemostatic parameters according to the intervention arm | Tissue factor, fibrinogen, PAI-1, vWF will be measured. | Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm | |
| Secondary | Changes from baseline in HL and LDL size according to the intervention arm | Plasmi lipoprotein size will be measured by polycacrylamide gradient gel electrophoresis | Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm | |
| Secondary | Changes in advanced glycation end products according to the intervention arm | Advanced glycation end products and soluble receptor of advanced glycation-end produtcs will be measured | Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm | |
| Secondary | Changes from baseline in gene expression in the peripheral cells according to the intervention arm | RNA from peripheral leukocytes will be isolated for the subsequent measurements of changes in gene expression of toll-like receptors, GLUT-4, C-peptide, resistin adn IL-6, and genes involved in telomere maintenance and oxidation | Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm | |
| Secondary | Changes from baseline in cellular glucose uptake according to the intervention arm | Glucose uptake and GLUT4 protein levels will be assessed in peripheral leukocytes | Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm | |
| Secondary | Changes from baseline in platelet function according to the intervention arm | Platelet number, mean platelet volume and platelet factor 4 in blood, and urinary levels of 11-dehydro-thromboxane B2 will be assessed. | Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm | |
| Secondary | Changes from baseline in telomeric length of leukocytes (LTL) | Telomere lenght will be evaluated as a biomarker of biological age and general health status. Telomere attrition may play an important role in the pathogenesis and severity of type 2 diabetes (T2D) increasing the probability of beta-cell senescence, leading to reduced cell mass and decreased insulin secretion. | Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first intervention arm. Measurements will be not analysed after the second period due to expected carry-over effect. |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
| Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
| Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
| Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
| Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
| Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
| Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
| Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
| Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
| Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
| Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
| Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
| Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
| Completed |
NCT02252224 -
Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance
|